Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Beluga Health vs LillyDirect Foundayo

Beluga Health
Graded #430

Lower grade

vs+11.400000000000006
LillyDirect Foundayo
Graded #165

Higher grade

The verdict

LillyDirect Foundayo takes it — 67.2/100 to 55.8/100.

LillyDirect Foundayo grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLillyDirect Foundayo +27
45
72
Dose & formulationLillyDirect Foundayo +19
40
59
Clinical oversightLillyDirect Foundayo +2
76
78
Labs & monitoringBeluga Health +10
62
52
FulfillmentLillyDirect Foundayo +16
64
80
Contract termsEven
55
55
Beluga Health · left barLillyDirect Foundayo · right bar

The numbers

MetricBeluga HealthLillyDirect Foundayo
WeighScore55.8/10067.2/100
GradeCC
Scorecard rank#430#165
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Beluga Health

Graded #430 · C

Strengths

  • Supports GLP-1 care with compounded semaglutide and tirzepatide
  • Board-certified providers and a 50-state medical infrastructure
  • LegitScript certified with SOC 2 and ISO 27001 security
  • Pharmacies follow FDA/USP standards with third-party batch testing
  • Powers many DTC brands as a turnkey telehealth backbone

Where it loses points

  • White-label B2B group, not a direct consumer-facing service
  • Offers compounded, not FDA-approved branded, GLP-1s
  • No public consumer pricing for the GLP-1 offering
  • Cited among nationwide groups tied to FDA telehealth GLP-1 scrutiny
  • Care quality varies by the consumer brand using the platform
LillyDirect Foundayo

Graded #165 · C

Strengths

  • Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
  • Direct from manufacturer — no compounding, no third-party reseller
  • Daily oral pill, no injections, no refrigeration
  • Available in all 50 states

Where it loses points

  • Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
  • Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
  • $25 savings card requires commercial insurance — Medicare and Medicaid not eligible
  • Strict empty-stomach 30-minute window may be hard for some patients to follow

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard